Meet Phathom

We believe we can change the status quo of treatment for acid-related disorders.
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid-related gastrointestinal (GI) disorders.

Our initial investigational candidate, vonoprazan, is a potassium competitive acid blocker (P-CAB) and represents a new class of anti-secretory medicines with potential applications in GI disorders.*

ABOUT US

Discover our in-depth experience in developing and commercializing innovative therapeutics

Our Science

View late clinical-stage programs for patients with erosive GERD and H. pylori infection

Investor Resources

Access our latest corporate information, upcoming events, press releases, and more

*Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration.

No representation is made as to the safety or effectiveness of vonoprazan.